Meftal painkiller: Meftal maker says adverse reaction flagged by IPC is very rare
Blue Cross Laboratories, the owner of the Meftal painkiller brand, has clarified that the adverse reaction the Indian Pharmacopoeia Commission (IPC) has flagged is a rare event. The company claims that the products constituent, mefenamic acid, can cause adverse reactions, including eosinophilia and systemic symptoms (DRESS) syndrome.
United Kingdom Pvpi Pharmacovigilance Programme Indian Pharmacopoeia Commission Blue Cross Laboratories Across Laboratories Pharmacovigilance Programme
Source: indiatimes.com